With the continuous development of medical technology, China has raised the age of female vaccination to 45. More and more people are vaccinated with nine-valent HPV vaccine in the later stage, but the clinical supply of nine-valent HPV vaccine in China is limited, which may lead to the difficulty in finding one vaccine and the price increase.
The first help: provide more women with the opportunity to get vaccinated. Under normal circumstances, adult women will make an appointment for a nine-valent HPV vaccine in a professional hospital or institution after receiving a certain salary. The waiting time is longer, generally more than one year. At the same time, many 25-year-old women may not have a chance to get vaccinated until they are 26 after making an appointment. But they are all past the vaccination age, and women over the age of 26 cannot be vaccinated. Expand the age group to help women over 26 and under 45 get opportunities.
The second help: protect women from infection. After human papillomavirus enters human body, it will cause a series of diseases in human body. And this virus will make women more likely to get sick than men. Therefore, many countries began to propose HPV vaccine for female exposure. In the market, there are three kinds of HPV vaccines, among which the nine-valent HPV vaccine is the highest. Prior to this, the nine-valent HPV vaccine had restrictions on the age of women. After the age limit is released, more women will be successfully vaccinated, effectively preventing women from being infected with the virus.
Generally speaking, it is a good thing to extend the vaccination age of female human papillomavirus. School-age women must choose to be vaccinated with human papillomavirus to protect their health.